Nasdaq-listed Amarin seeks additional listing on AIM and IEX markets

By E. Janene Geiss

Philadelphia, June 9 - Amarin Corp. plc said Friday that it intends to seek secondary listings on the AIM Market of the London Stock Exchange and the IEX Market of the Irish Stock Exchange.

Amarin said it will retain its primary listing on Nasdaq and is not seeking any additional capital as part of the listing process, according to a company news release.

Amarin said it already is well funded with $33 million in cash as of March 31. Admission to AIM and IEX is expected to occur in mid-July, officials said.

Listing on AIM and IEX will enhance Amarin's profile among commercial and financial audiences in Europe, officials said. It also will enable European investors to trade Amarin shares on an open market whether it be Nasdaq, AIM or IEX.

Davy is acting as nominated adviser (Nomad), IEX adviser and broker to Amarin in respect of the admission.

"While the majority of our investors are based in the United States, AIM and IEX listings will offer greater flexibility to our existing and future European and international investors and will enhance our European visibility," Rick Stewart, chief executive officer, said in the release.

Amarin is a London neuroscience company focused on the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.